Valuation : Fate Therapeutics, Inc.

Market Cap 29Cr 25Cr 23Cr 21Cr 40Cr 2.74TCr 40Cr 277.41Cr 107.65Cr 1.4TCr 108.88Cr 106.51Cr 4.53TCr P/E 2026 *
-2.27x
P/E 2027 * -2.34x
Enterprise Value 29Cr 25Cr 23Cr 21Cr 40Cr 2.74TCr 40Cr 277.41Cr 107.65Cr 1.4TCr 108.88Cr 106.51Cr 4.53TCr EV / Sales 2026 *
51.3x
EV / Sales 2027 * 60.8x
Free-Float
98.94%
Yield 2026 *
-
Yield 2027 * -
1 day+2.48%
1 week+2.06%
Current month+3.77%
1 month-3.50%
3 months+12.22%
6 months+71.03%
Current year+152.39%
1 week 2.34
Extreme 2.335
2.5
1 month 2.23
Extreme 2.23
2.88
Current year 0.97
Extreme 0.97
3.23
1 year 0.93
Extreme 0.9335
3.23
3 years 0.66
Extreme 0.66105
8.83
5 years 0.66
Extreme 0.66105
75.79
10 years 0.66
Extreme 0.66105
121.16
Manager TitleAgeSince
Chief Executive Officer 49 01/01/2025
Director of Finance/CFO 47 20/10/2025
Chief Operating Officer - 01/07/2021
Director TitleAgeSince
Chairman 78 01/12/2011
Director/Board Member 70 17/03/2014
Director/Board Member 47 31/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
04/08/26 Sell

Chief Executive Officer

-43,947 0.0377%
04/08/26 Sell

Compliance Officer

-38,800 0.0333%
12/06/26
Redmile Group LLC
FreeCompany 87,900 0.0754%
Change 5-day change 1-year change 3-year change Capi.($)
+2.48%+2.06%+154.91%-8.49% 29Cr
-1.79%-3.82%+38.74%+91.90% 6.9TCr
-2.06%-1.52%+46.40%+86.87% 6.63TCr
-0.31%+6.54%-11.39%+378.92% 2.77TCr
+0.86%+1.65%+0.25%-14.95% 2.58TCr
-3.00%-2.61%+34.45%+11.39% 2.65TCr
-1.46%-0.09%+24.64%-18.36% 2.04TCr
-2.96%-16.03%+213.13%+375.00% 1.76TCr
-1.49%-6.69%-4.69%+539.74% 1.51TCr
-0.20%+8.37%+57.87%+164.98% 1.47TCr
Average -0.95%-1.07%+55.43%+160.70% 2.84TCr
Weighted average by Cap. -1.49%-0.46%+40.35%+138.73%

Financials

2026 *2027 *
Net sales 56.49L 48.61L 45.74L 41.78L 78.16L 53Cr 78.37L 5.4Cr 2.1Cr 27Cr 2.12Cr 2.08Cr 88Cr 47.67L 41.02L 38.59L 35.25L 65.95L 45Cr 66.13L 4.56Cr 1.77Cr 23Cr 1.79Cr 1.75Cr 74Cr
Net income -13Cr -11Cr -10Cr -9.53Cr -18Cr -1.22TCr -18Cr -123.25Cr -48Cr -624.06Cr -48Cr -47Cr -2.01TCr -15Cr -13Cr -12Cr -11Cr -20Cr -1.38TCr -20Cr -139.7Cr -54Cr -707.36Cr -55Cr -54Cr -2.28TCr
Net Debt - -
Logo Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.
Employees
161
Date Price Change Volume
05/26/05 $2.480 +2.48% 6,09,926
03/26/03 $2.420 -1.22% 7,15,437
02/26/02 $2.450 +0.82% 12,18,923
01/26/01 $2.430 +1.67% 10,41,342
31/26/31 $2.390 -1.65% 5,49,268
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
2.420USD
Average target price
5.744USD
Spread / Average Target
+137.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FATE Stock